- Mechanism
- Disrupts microbial membranes and modulates immune cell chemotaxis
- Typical research dose
- 100-200 mcg/day subcutaneous or topical (research only)
- Route
- subcutaneous, topical
- Half-life
- Unknown (rapidly degraded in vivo)
- Legal status
- Research Only
Overview
The LL-37 peptide is the only known human cathelicidin, functioning as a cornerstone of the innate immune system. This multifaceted antimicrobial agent exhibits broad-spectrum activity against bacteria, viruses, and fungi while simultaneously modulating immune responses to resolve complex infections. Research indicates that LL-37 benefits extend far beyond simple pathogen destruction, playing vital roles in tissue regeneration, angiogenesis, and biofilm eradication. Understanding its pleiotropic nature is essential for developing novel therapeutic strategies against antibiotic-resistant superbugs and chronic inflammatory disorders.
Potential Benefits
- Broad-Spectrum Antimicrobial Action: Neutralizes bacteria, viruses, and fungi by disrupting their cellular membranes, showing potential as an anti-HIV agent (Vera-Cruz et al., 2021).
- Biofilm Disruption: Exhibits significant antibiofilm properties, preventing the formation and promoting the eradication of resilient bacterial colonies (Memariani et al., 2023).
- Tissue Regeneration and Wound Healing: Accelerates the healing rate of diabetic foot ulcers and promotes bone and periodontium regeneration (Chinipardaz et al., 2022).
- Immune System Modulation: Regulates inflammatory responses by recruiting immune cells and modulating cytokine production for a balanced immunomodulatory response (Leite et al., 2023).
- Cardiovascular Protection: Actively mitigates heart disease progression through its regulatory effects on cellular inflammation and tissue repair (Miao et al., 2024).
- Anticancer Potential: Suppresses tumor growth by modulating the tumor microenvironment and enhancing cancer immunity (Keshri et al., 2025).
Where to Buy LL-37
Ascension Peptides
View →Research compound. LL-37 is a research chemical, typically not FDA-approved for human consumption. Sale or use for human consumption may be illegal in your jurisdiction.
No compensation. PeptideStack does not endorse, verify, or receive compensation from any vendor. No affiliate or referral relationships.
Verify third-party COAs and consult a qualified healthcare provider before using any compound.
Side Effects
Common side effects:
- Injection site erythema and localized irritation
- Mild, transient localized swelling
- Pruritus (itching) at the administration site
- Temporary localized pain or tenderness
- Mild systemic fatigue during initial dosing
Rare or serious side effects:
- Exacerbation of certain autoimmune conditions like rosacea
- Unintended pro-inflammatory responses in specific tissues
- Potential promotion of NETosis-related tissue damage
- Severe allergic reactions or anaphylaxis
LL-37 is not FDA-approved and is intended for research purposes only. Consult a qualified healthcare provider before use.
Mechanism of Action
Direct pathogen neutralization represents the primary mechanism of the LL-37 peptide, achieved through its amphipathic alpha-helical structure. Upon encountering microbial membranes, the positively charged peptide binds to negatively charged pathogen surfaces, inserting itself to form transmembrane pores that cause cellular leakage and death. This physical disruption effectively bypasses traditional antibiotic resistance mechanisms, making it highly effective against resilient biofilms (Memariani et al., 2023). Receptor-mediated immune modulation constitutes the secondary, yet equally critical, function of LL-37. The peptide interacts with various cell surface receptors, including FPR2, to stimulate chemotaxis, angiogenesis, and the release of immunomodulatory cytokines. Furthermore, it actively participates in NETosis, the formation of neutrophil extracellular traps, which helps contain infections but requires strict regulation to prevent tissue damage (Radic et al., 2022).
Origin & History
The discovery of LL-37 stems from early research into human innate immunity, where it was identified as the C-terminal peptide cleaved from the human CAP18 protein (hCAP18). As the only known human cathelicidin, it is naturally produced by neutrophils, epithelial cells, and macrophages in response to infection or injury. Endogenous production is heavily influenced by Vitamin D levels, a relationship explored in numerous clinical trials investigating Vitamin D supplementation for conditions like tuberculosis and ICU recovery (NCT00788320). Clinical development milestones have increasingly focused on harnessing LL-37 benefits for targeted therapeutic applications, particularly in wound healing and periodontitis (He et al., 2025). Despite promising phase 2 trials evaluating topical creams for diabetic foot ulcers (NCT04098562), the synthetic LL-37 peptide remains strictly designated for research purposes. Regulatory agencies have not yet approved it for human medical use, necessitating further investigation into its long-term safety and optimal delivery methods.